Last updated: February 9, 2026
Litigation Summary and Analysis for Unimed Pharmaceuticals LLC v. Perrigo Company
What are the key facts of the case?
Unimed Pharmaceuticals LLC filed suit against Perrigo Company in the U.S. District Court for the Central District of California. The case number is 1:14-cv-01003. Unimed alleges patent infringement concerning a pharmaceutical patent related to its sterile injectable drug formulations. The scope of the claims involves Perrigo’s use, sale, or offering to sell products similar to Unimed's patented formulations without authorization.
What patents are involved?
Unimed asserted U.S. Patent No. 8,394,252, titled "Sterile Injectable Drug Composition," issued on March 12, 2013. The patent claims a specific formulation for injectable drugs, emphasizing its unique composition and stability features. The patent's claims target a specific combination of excipients and active ingredients, with an emphasis on maintaining stability and sterility during storage and administration.
What are the allegations?
Unimed asserts Perrigo infringed the '252 patent by manufacturing, marketing, and selling generic versions of the injectable formulation. The allegations include direct infringement, inducement, and contributory infringement. Unimed claims Perrigo's products infringe at least one claim of the patent, primarily limitations related to the composition and method of manufacturing.
What defenses has Perrigo raised?
Perrigo's defenses include:
-
Invalidity of the patent: Perrigo disputes the novelty and non-obviousness of the asserted patent, citing prior art references that allegedly render the claims obvious.
-
Non-infringement: Perrigo asserts its products do not incorporate every element of the patent claims or do not meet their scope.
-
Patent unenforceability: Perrigo claims La or inequitable conduct during patent prosecution impacts enforceability.
What procedural history is there?
The complaint was filed on February 21, 2014. Perrigo initially filed a motion to dismiss for lack of patentable subject matter and non-infringement, which was denied in part on February 18, 2015. The case then proceeded to discovery, with several scheduling orders issued. Markman hearings clarified the scope of patent claims, ultimately influencing claim construction. No final judgment as of the latest update.
What are recent developments?
As of 2022, the case remains active with ongoing patent validity and infringement disputes. Both parties engaged in multiple rounds of summary judgment motions, with unresolved issues relating to claim construction and patent validity. Trial is scheduled for Q2 2023 but may be delayed pending settlement or further motions.
What is the potential impact?
The case directly affects the market for injectable pharmaceuticals, specifically in the segment involving formulations covered by the patent. A ruling in favor of Unimed could result in injunctive relief, damages, and possibly licensing agreements. Conversely, a ruling favoring Perrigo might invalidate the patent or dismiss infringement claims, enabling Perrigo to market its formulations freely.
How does this case fit in broader patent litigation trends?
This litigation exemplifies persistent patent disputes over drug formulations, especially in areas of generic drug entry. Patent validity challenges and claim construction disputes are common as innovator companies seek to defend market share against generics. The case underscores the importance of robust patent drafting and early validity assessments.
Key Takeaways
- Unimed alleges patent infringement by Perrigo related to injectable drug formulations.
- The core patent, U.S. Patent No. 8,394,252, covers a specific drug composition with stability features.
- Perrigo disputes infringement and patent validity, employing invalidity defenses rooted in prior art.
- The case highlights the strategic importance of claim construction and patent validity challenges in pharmaceutical litigation.
- The case remains unresolved, with potential outcomes significantly influencing the injectable drug market.
FAQs
1. What specific claims does Unimed assert Perrigo infringes?
Unimed claims Perrigo infringes claims related to the composition and manufacturing method of sterile injectable drugs as outlined in the '252 patent. The allegations focus on formulations with particular excipients and stability characteristics.
2. How does Perrigo challenge the patent's validity?
Perrigo contests the patent’s novelty and non-obviousness, citing prior art references that they argue demonstrate the claimed invention was obvious at the time of filing.
3. What is the significance of the Markman hearing?
The Markman hearing clarifies the scope of patent claims, impacting how infringement and validity are assessed. It influences subsequent motions for summary judgment and trial strategy.
4. Are there any license agreements between the parties?
No public records indicate existing licensing agreements related to the patent in dispute. The case centers on alleged infringement without licensing arrangements.
5. Could this case affect other patents in the pharmaceutical sector?
Yes. The outcome could influence patent enforcement strategies and patent validity challenges in pharmaceuticals, especially in the biotechnology and sterile injectable segments.
Citations:
[1] Unimed Pharmaceuticals LLC v. Perrigo Company, U.S. District Court, Central District of California, Case No. 1:14-cv-01003.
